National Medical Insurance Administration: The clinical efficacy and safety of generic drugs selected through centralized procurement are equivalent to those of the original drugs

On the 17th, the National Medical Insurance Administration held a press conference to introduce the real-world research results on the clinical efficacy and safety of generic drugs selected from the second and third batches of nationally organized drug centralized procurement.

In June 2021, entrusted by the National Medical Insurance Administration, Xuanwu Hospital of Capital Medical University led 29 medical institutions in 16 provinces across the country to conduct clinical efficacy studies on the second and third batches of 23 representative varieties organized by the state. and safety real-world studies. Over the past two years, a total of 38 brands of selected generic drugs have been evaluated. The research results show that the clinical efficacy and safety of the selected generic drugs are equivalent to those of the original drugs.